Our collaboration partner innoVitro GmbH offers high quality screening services using Nanion's Instruments
innoVitro is a biotech company from Jülich, Germany, with core competence in the measurement of cellular forces, in particular of stem cell derived cardiomyocytes. The company was founded in 2018 as a spin-off from the University of Applied Sciences Aachen. In a collaborative effort between innoVitro and Nanion Technologies, the CellDrum technology developed at the University was fused with the CardioExcyte 96 platform resulting in the FLEXcyte 96 system. innoVitro is the producer and exclusive supplier of FLEXcyte 96 plates. Additionally, innoVitro offers toxicity and efficacy services on the platform.
innoVitro's services include:
Screening services on the FLEXcyte 96 delivering functional measurements at physiological mechanical conditions. Acute or chronic (up to 5+ days) cardiac toxicity or efficacy assessment is possible, with comprehensive parameter measurements from human iPSC-derived cardiomyocytes, including:
- Contraction amplitude
- Beat rate
- Upstroke and downstroke velocity
- Duration and integral
- Arrhythmic events
Data example - Isoproterenol analyzed on the FLEXcyte 96:
Isoproterenol is a beta-adrenergic agonist and well known for its positive inotropic effects on human cardiomyocytes. Common in vitro assays fail to reflect this physiologic response, shading doubt on the maturity of stem cell-derived cardiomyocytes. Within the physiologic mechanical environment of the FLEXcyte 96 system, positive inotropic responses of stem cell-derived cardiomyocytes can be achieved in standard, serum-containing media.
Stem cell-derived cardiomyocytes display positive force-frequency-relation when cultured on the biomimetic membranes of the FLEXcyte 96 platform.